Phase 1 Breast Cancer Trial, Recruiting NCT06900647 Sponsor: Sun Yat-sen University Condition: Breast Cancer
Back to Breast Cancer

Phase 1 Breast Cancer Trial, Recruiting

NCT06900647
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older who have been formally diagnosed with breast cancer that has come back or spread to other parts of the body
  • People who have tumour tissue samples available that have been preserved in a standard way used by laboratories (confirm with trial site)
  • People whose breast cancer has continued to grow or spread after already trying standard treatments
  • People who have at least one tumour that can be measured on a scan
  • People who are reasonably active and able to care for themselves, based on a standard medical scoring system (confirm with trial site for the specific score range)
  • People who are expected to live for at least 12 weeks
  • People whose blood, liver, and kidney function meet certain minimum levels set by the trial (confirm specific values with trial site)
  • Women who could become pregnant must have had a negative pregnancy test within 7 days before joining, and must agree to use reliable contraception during the trial and for 8 weeks after the last dose
  • People who are willing to follow the trial schedule, attend follow-up appointments, and cooperate with the study team

Who may not be able to join:

  • People with active hepatitis B or active hepatitis C infection
  • People with any serious ongoing illness, significant other health conditions, or an active infection
  • People currently receiving any other cancer treatment
  • People with a history of epilepsy or seizure-related conditions
  • People who are pregnant or breastfeeding
  • People who are unlikely to attend follow-up appointments or follow the trial requirements
  • People who are known to be allergic to the study drugs
  • People diagnosed with another type of cancer within the past 5 years, with some exceptions for certain treated skin cancers, cervical changes, or other cancers with no current evidence of disease (confirm specific exceptions with trial site)
  • People whom the trial doctor determines should not participate for other reasons that could affect the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yan-xia Shi, Doctor, Sun Yat-sen University

Phone: 86-020-87343486

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicities (DLTs); Maximum Tolerated Dose (MTD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov